SAN DIEGO – (COMMERCIAL THREAD) – Kurin Inc., the inventor and manufacturer of 510 (k) approved Kurin® blood culture collection sets, today announced that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference. This is the first study of Kurin, a passive low volume blood culture collection device with flash technology in a pediatric population. The study was conducted over two periods and in combination, Kurin was used on 1,175 cultures without a single contamination.
“Easily” It is also noteworthy that this is the first study that uses our PIV products, which allow nurses the flexibility to extract a culture from a freshly placed IV, which is particularly important in this population of patients. “;
Kurin is the first device to enable passive isolation of initial blood flow, providing clinicians with a seamless path to compliance. Results are determined by compliance, and compliance is a function of how simple technology is incorporated into practice, which can be particularly difficult in the busy emergency department and for these young patients. Kurin was also designed to use remarkably low blood volume, a significant improvement over other options, setting aside only 0.15ml to achieve these clinical results, another critical requirement for pediatric patients.
“At the beginning, the clinicians at Oishei Children’s provided us with feedback on how to modify our product for their patient population resulting in a small version of our PIV and using a minimal amount. blood, ”Rogers said. “Working with clients to optimize patient health is an important part of why we are here. Our goal is to dramatically improve patient outcomes while saving hospitals significant dollars and, given the special place children have in our hearts, it is especially heartwarming to see the impact that has been made here. ”
About Kurin®, Inc.
Kurin Inc., a Certified Minority Company (MBE), focuses on the design, development, manufacture, marketing and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received 510 (k) marketing authorization from the FDA. For more information, visit the website at www.kurin.com.